Pharma Zoute: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Pharma Zoute
Largest movements
- Deferred charges and accrued income +€29,174
up €29,174 (+1,152%), from €2,533 to €31,706
- Cash +€27,206
up €27,206 (+8.8%), from €308,004 to €335,209
mainly Depreciation (+€29,600) and Stocks and contracts (+€23,164)
- Stocks and contracts -€23,164
down €23,164 (-11.7%), from €198,545 to €175,381
- Intangible fixed assets -€18,000
down €18,000 (-12.5%), from €144,000 to €126,000
- Receivables within one year -€15,657
down €15,657 (-43.6%), from €35,884 to €20,227
of which Trade receivables: -€14,557
- Profit (loss) carried forward -€24,555
new in 2025: -€24,555
- Other debts +€14,551
up €14,551 (+3.0%), from €488,379 to €502,930
- Reserves -€7,999
down €7,999 (-5.7%), from €139,797 to €131,798
of which Distributable reserves: -€7,999
- Gross operating margin -€15,792
down €15,792 (-14.6%), from €107,943 to €92,152
- Financial charges -€2,602
down €2,602 (-15.2%), from €17,069 to €14,467
- Staff costs +€2,032
up €2,032 (+2.6%), from €79,137 to €81,168
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €727,004 | €714,962 | -€12,041 | -1.7% |
| Fixed assets | 21/28 | €182,039 | €152,439 | -€29,600 | -16.3% |
| Intangible fixed assets | 21 | €144,000 | €126,000 | -€18,000 | -12.5% |
| Tangible fixed assets | 22/27 | €28,739 | €17,139 | -€11,600 | -40.4% |
| Land and buildings | 22 | €12,805 | €6,403 | -€6,402 | -50.0% |
| Plant, machinery and equipment | 23 | €1,190 | €825 | -€365 | -30.7% |
| Furniture and vehicles | 24 | €14,744 | €9,911 | -€4,832 | -32.8% |
| Financial fixed assets | 28 | €9,300 | €9,300 | = | 0.0% |
| Current assets | 29/58 | €544,965 | €562,524 | +€17,558 | +3.2% |
| Stocks and contracts in progress | 3 | €198,545 | €175,381 | -€23,164 | -11.7% |
| Stocks | 30/36 | €198,545 | €175,381 | -€23,164 | -11.7% |
| Amounts receivable within one year | 40/41 | €35,884 | €20,227 | -€15,657 | -43.6% |
| Trade receivables | 40 | €23,785 | €9,228 | -€14,557 | -61.2% |
| Other amounts receivable | 41 | €12,099 | €10,999 | -€1,101 | -9.1% |
| Cash at bank and in hand | 54/58 | €308,004 | €335,209 | +€27,206 | +8.8% |
| Deferred charges and accrued income | 490/1 | €2,533 | €31,706 | +€29,174 | +1,152% |
| Total equity and liabilities | 10/49 | €727,004 | €714,962 | -€12,041 | -1.7% |
| Equity | 10/15 | €158,397 | €125,843 | -€32,554 | -20.6% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €139,797 | €131,798 | -€7,999 | -5.7% |
| Tax-exempt reserves | 132 | €887 | €887 | = | 0.0% |
| Distributable reserves | 133 | €138,910 | €130,911 | -€7,999 | -5.8% |
| Profit (loss) carried forward | 14 | - | -€24,555 | -€24,555 | |
| Amounts payable | 17/49 | €568,607 | €589,120 | +€20,513 | +3.6% |
| Amounts payable within one year | 42/48 | €558,531 | €581,313 | +€22,782 | +4.1% |
| Trade debts | 44 | €42,690 | €48,664 | +€5,974 | +14.0% |
| Suppliers | 440/4 | €42,690 | €48,664 | +€5,974 | +14.0% |
| Taxes, remuneration and social security | 45 | €27,463 | €29,720 | +€2,257 | +8.2% |
| Taxes | 450/3 | €4,655 | €3,925 | -€730 | -15.7% |
| Remuneration and social security | 454/9 | €22,808 | €25,795 | +€2,986 | +13.1% |
| Other amounts payable | 47/48 | €488,379 | €502,930 | +€14,551 | +3.0% |
| Accrued charges and deferred income | 492/3 | €10,076 | €7,806 | -€2,270 | -22.5% |
| Remuneration, social security and pensions | 62 | €79,137 | €81,168 | +€2,032 | +2.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €29,623 | €29,600 | -€24 | -0.1% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | - | -€586 | -€586 | |
| Other operating charges | 640/8 | €910 | €935 | +€25 | +2.7% |
| Gross operating margin | 9900 | €107,943 | €92,152 | -€15,792 | -14.6% |
| Operating profit (loss) | 9901 | -€1,727 | -€18,965 | -€17,238 | -998% |
| Financial income | 75/76B | €1,317 | €878 | -€439 | -33.3% |
| Recurring financial income | 75 | €1,317 | €878 | -€439 | -33.3% |
| Financial charges | 65/66B | €17,069 | €14,467 | -€2,602 | -15.2% |
| Recurring financial charges | 65 | €17,069 | €14,467 | -€2,602 | -15.2% |
| Profit (loss) for the period before taxes | 9903 | -€17,479 | -€32,554 | -€15,075 | -86.2% |
| Profit (loss) for the period | 9904 | -€17,479 | -€32,554 | -€15,075 | -86.2% |
| Profit (loss) for the period to be appropriated | 9905 | -€17,479 | -€32,554 | -€15,075 | -86.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 19 October 2026 via checked.be.